Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : GSK plc

Company GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London Stock Exchange
Other stock markets
 11:35:05 2023-12-01 am EST 		Intraday chart for GSK plc 5-day change 1st Jan Change
1,436.00 GBX +1.17% +0.94% -0.11%
Dec. 01 GSK to Discontinue Manufacturing Integrilin Due to Ingredient Supply Issue MT
Dec. 01 EMA: GLAXOSMITHKLINE IN AGREEMENT WITH EMA INFORMED GSK WILL DIS… RE

Business Summary

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).

Number of employees : 69,400

Sales per Business

GBP in Million2021Weight2022Weight Delta
Commercial Operations
100.0 %
- - 29,324 100.0 % -

Sales per region

GBP in Million2021Weight2022Weight Delta
United States
49.6 %
15,093 44.2 % 14,542 49.6 % -3.65%
Rest of World
48.0 %
11,183 32.8 % 14,087 48.0 % +25.97%
United Kingdom
2.4 %
975 2.9 % 695 2.4 % -28.72%

Managers

Managers TitleAgeSince
Emma Walmsley CEO
 Chief Executive Officer 54 2010
Shobie Ramakrishnan CTO
 Chief Tech/Sci/R&D Officer - 2017
Tony Wood CTO
 Chief Tech/Sci/R&D Officer - 2017
James Ford CMP
 Compliance Officer - 1995
Amy Altshul CTO
 Chief Tech/Sci/R&D Officer - -
Hal Barron BRD
 Director/Board Member 61 2017
Christopher Corsico PRN
 Corporate Officer/Principal 61 -
María Cristina de Luna Basagoiti PRN
 Corporate Officer/Principal - 2010
Phil Thomson PRN
 Corporate Officer/Principal - 2010
Diana Conrad HRO
 Human Resources Officer - 2015

Members of the board

Members of the board TitleAgeSince
Jonathan Symonds CHM
 Chairman 65 2019
Urs Rohner BRD
 Director/Board Member 64 2014
Hal Barron BRD
 Director/Board Member 61 2017
Vishal Sikka BRD
 Director/Board Member 56 2022
Charles Bancroft BRD
 Director/Board Member 64 2020
Anne Beal BRD
 Director/Board Member 61 2021
Emma Walmsley CEO
 Chief Executive Officer 54 2010
Elizabeth Anderson BRD
 Director/Board Member 66 2022
Jesse Goodman BRD
 Director/Board Member 72 2015
Harry Dietz BRD
 Director/Board Member 65 2021

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,312,101,988 4,002,857,837 ( 92.83 %) 217,068,169 ( 5.034 %) 92.83 %

Shareholders

NameEquities%Valuation
Dodge & Cox
3.645 %
149,262,697 3.645 % 2 640 M p
The Vanguard Group, Inc.
3.460 %
141,681,483 3.460 % 2 506 M p
Norges Bank Investment Management
2.333 %
95,556,556 2.333 % 1 690 M p
BlackRock Investment Management (UK) Ltd.
1.998 %
81,825,154 1.998 % 1 447 M p
BlackRock Fund Advisors
1.743 %
71,360,494 1.743 % 1 262 M p
Silchester International Investors LLP
1.627 %
66,609,000 1.627 % 1 178 M p
BlackRock Advisors (UK) Ltd.
1.393 %
57,056,303 1.393 % 1 009 M p
Schroder Investment Management Ltd.
1.360 %
55,697,868 1.360 % 985 M p
SIX SIS Ltd.
1.168 %
47,832,000 1.168 % 846 M p
Vanguard Global Advisers LLC
1.039 %
42,534,189 1.039 % 752 M p
NameEquities%Valuation
PRIMECAP Management Co.
0.5569 %
11,401,720 0.5569 % 407 M p
Holocene Advisors, LP
0.2449 %
5,014,059 0.2449 % 179 M p
Eversept Partners LP
0.1592 %
3,259,342 0.1592 % 116 M p
Renaissance Technologies LLC
0.1422 %
2,911,993 0.1422 % 104 M p
Camber Capital Management LP
0.1392 %
2,850,000 0.1392 % 102 M p
Millennium Management LLC
0.1282 %
2,624,131 0.1282 % 94 M p
Douglas Lane & Associates LLC
0.1129 %
2,311,891 0.1129 % 83 M p
Morgan Stanley & Co. International Plc
0.0962 %
1,969,447 0.0962 % 70 M p
Macquarie Investment Management Business Trust
0.0832 %
1,703,753 0.0832 % 61 M p
Magnetar Financial LLC
0.0793 %
1,623,560 0.0793 % 58 M p
NameEquities%Valuation
Professionals’ Financial – Mutual Funds Inc.
0.000272 %
44,590 0.000272 % 967 588 p
Counsel Portfolio Services, Inc.
0.000191 %
31,235 0.000191 % 677 789 p
Horizons ETFs Management (Canada), Inc.
0.000010 %
1,605 0.000010 % 34 828 p

Holdings

NameEquities%Valuation
GLAXOSMITHKLINE S.A.E
91.20%
 76,161,378 91.20% 79,079,882 $
HALEON PAKISTAN LIMITED
85.79%
 100,423,259 85.79% 55,653,566 $
GLAXOSMITHKLINE PAKISTAN LIMITED
82.59%
 263,029,794 82.59% 70,018,531 $
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED
75.00%
 127,054,524 75.00% 2,171,755,684 $
LYELL IMMUNOPHARMA, INC.
12.05%
 30,253,189 12.05% 50,069,028 $
WAVE LIFE SCIENCES LTD.
10.79%
 10,683,761 10.79% 57,478,634 $
ORCHARD THERAPEUTICS PLC
9.85%
 12,455,252 9.85% 19,816,306 $
DONG-A ST CO., LTD.
8.22%
 707,859 8.22% 29,089,020 $
HALEON PLC
7.99%
 738,132,722 7.99% 2,951,290,825 $
CUREVAC N.V.
7.41%
 16,591,937 7.41% 87,937,266 $

Company contact information

GSK Plc

980 Great West Road Brentford

TW8 9GS, Middlesex

+44 20 8047 5000

http://www.gsk.com/en-gb/
address GSK plc(GSK)

Group companies

NameCategory and Sector
GlaxoSmithKline Capital Plc
Finance - Finance/Rental/Leasing
GlaxoSmithKline Biologicals SA
Health Technology - Biotechnology
Eskaylab Ltd.
Commercial Services - Miscellaneous Commercial Services
Horlicks Ltd.
Consumer Non-Durables - Beverages: Alcoholic
Novartis Consumer Health SA
Health Technology - Pharmaceuticals: Major
Glaxo Group Ltd.
Health Technology - Pharmaceuticals: Major
GlaxoSmithKline Finance Plc
Finance - Finance/Rental/Leasing
Setfirst Ltd.
Finance - Financial Conglomerates
GlaxoSmithKline GmbH & Co. KG
Health Technology - Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for GSK plc

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
14.36GBP
Average target price
17.25GBP
Spread / Average Target
+20.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GSK PLC Stock GSK plc
-0.11% 74 192 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.64% 525 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+48.98% 454 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-10.34% 381 B $
ABBVIE INC. Stock AbbVie Inc.
-11.26% 253 B $
ROCHE HOLDING AG Stock Roche Holding AG
-17.52% 221 B $
NOVARTIS AG Stock Novartis AG
+2.14% 202 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.09% 200 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.58% 163 B $
AMGEN INC. Stock Amgen Inc.
+3.74% 146 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock GSK plc - London Stock Exchange
  4. Company GSK plc
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer